Following the European Medicines Agency’s CHMP recommendation, the European Commission (EC) has just approved the first two infliximab biosimilar products, Inflectra (from Hospira) and Remsima (from Celltrion), both referenced to Remicade (The Pharma Letter September 11).
The European Generic medicines Association (EGA) welcomes these approvals which reinforce Europe’s leading role in biosimilar medicines. Most importantly, this move creates the conditions for member states to increase access to treatment for patients with auto-immune illnesses such as rheumatoid arthritis and inflammatory bowel disease.
With quality, safety and efficacy thoroughly assessed by the European Medicines Agency’s scientific regulatory body, member states' price and reimbursement authorities will now look to establish the appropriate conditions for the fast market entry of these medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze